Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength

vs
industry
vs
history
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth

vs
industry
vs
history
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» SVA's 30-Y Financials

Financials (Next Earnings Date: 2017-11-28 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2016

SVA Guru Trades in Q3 2016

Jim Simons 1,475,000 sh (+5.65%)
» More
Q4 2016

SVA Guru Trades in Q4 2016

Jim Simons 1,524,800 sh (+3.38%)
» More
Q1 2017

SVA Guru Trades in Q1 2017

Jim Simons 1,679,490 sh (+10.14%)
» More
Q2 2017

SVA Guru Trades in Q2 2017

Jim Simons 1,814,300 sh (+8.03%)
» More
» Details

Insider Trades

Latest Guru Trades with SVA

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:SHSE:603139, SZSE:002873, SHSE:603229, SZSE:300653, SZSE:300404, SZSE:000004, SHSE:600556, SZSE:002868, SZSE:002566, SHSE:603538, SHSE:600866, HKSE:01035, SZSE:300049, SZSE:300181, SZSE:002286, HKSE:01681, HKSE:06826, SHSE:603896, SZSE:300583, SZSE:300497 » details
Traded in other countries:SVQ.Germany,
Headquarter Location:China
Sinovac Biotech Ltd is a biopharmaceutical company engaged in research, development, manufacturing and commercialization of vaccines that protect against human infectious diseases.

Sinovac Biotech Ltd, formerly known as Net-Force System Inc., was incorporated in Antigua and Barbuda on March 1, 1999. The Company is an integrated China-based biopharmaceutical company that focuses on the research, development, manufacturing and commercialization of vaccines that protect against human infectious diseases including hepatitis A, hepatitis A and B, seasonal influenza, H5N1 and H1N1 pandemic influenza and mumps, as well as animal rabies vaccine. The Company is engaged in the development, manufacturing and sales of vaccines for infectious diseases. Its product consist of Healive, for the treatment of Hepatitis A; Bilive, for the treatment of Hepatitis A&B; Anflu, for the treatment of Influenza; Panflu Whole Viron Pandemic Influenza Vaccine, for Pandemic Influenza Virus; Split Viron Pandemic Influenza Vaccine, for the treatment of Pandemic Influenza Virus; Panflu.1, for the treatment of Influenza A H1N1 virus; RabEnd, for the treatment of Rabies Virus in animals; Mumps Vaccine, for the treatment of mumps; EV71 Vaccine, Pneumococcal Polysaccharide Vaccine, Varicella Vaccine, for the treatment of varicella-zoster virus, H7N9 Vaccine, for the treatment of H7N9 influenza. The Company has four manufacturing bases located in Haidian and Changping Districts of Beijing, Dalian City of Liaoning Province, and Tangshan City of Hebei Province and also has two upstream production facilities in Haidian District, Beijing. It has built a new production site in in Changping District, Beijing, which comprises a new filing and packaging line that complies with the new PRC GMP standards, EV71 production facilities and a warehouse. The Company relies on its sales force to sell its products directly to CDCs in the private market. As of December 31, 2013, the in-house sales and marketing team consisted of 170 staff members located in 31 provinces throughout China. The Company obtains the raw materials from local and overseas suppliers. It maintains two suppliers for each key raw material, with the exception of hepatitis B antigens for Bilive production. The hepatitis B antigens are sourced from Beijing Temple of Heaven. The Company competes with Kunming Institute of Biological Product, Pukang Biological Co., Ltd., Changchun Institute of Biological Products and Changchun Changsheng Life Sciences Ltd for hepatitis A vaccine. It competes with Hualan Biological Engineering Inc., Changchun Institute of Biological Products, GSK, Aleph Biological Co., Ltd. and Zhejiang Tianyuan for influenza vaccines. The Company is subject to PRC laws and regulations governing the use, manufacture, storage, handling or disposal of hazardous materials and waste products.

Top Ranked Articles about Sinovac Biotech Ltd

Sinovac Reports Preliminary Top-Line Results from Phase III Clinical Trial for Varicella Vaccine Candidate Against Chickenpox
DEADLINE FRIDAY: Khang & Khang LLP Announces Securities Class Action Lawsuit against Sinovac Biotech Ltd. and Reminds Investors with Losses to Contact the Firm
ONE WEEK DEADLINE: Lundin Law PC Announces Securities Class Action Lawsuit against Sinovac Biotech Ltd. and Encourages Investors with Losses to Contact the Firm
DEADLINE ALERT: Brower Piven Reminds Shareholders Of Approaching Deadline In Class Action Lawsuit And Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Sinovac Biotech Ltd. (Nasdaq: SVA) To Contact The Firm
SINOVAC LOSS NOTICE: Rosen Law Firm Reminds Sinovac Biotech Ltd. Investors of Important Deadline in First Filed Class Action - SVA
Sinovac Biotech Announces Certain Updates Relating to Delayed Filing of Annual Report on Form 20-F
The Klein Law Firm Reminds Investors of Commencement of a Class Action Filed on Behalf of Sinovac Biotech Ltd. Shareholders and a Lead Plaintiff Deadline of September 1, 2017 (SVA)
SVA SHAREHOLDER ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Sinovac Biotech Ltd. and a Lead Plaintiff Deadline of September 1, 2017
EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Sinovac Biotech Ltd. - SVA
INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Sinovac Biotech Ltd. of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of September 1, 2017 – SVA

Ratios

vs
industry
vs
history

Buy Back

vs
industry
vs
history

Valuation & Return

vs
industry
vs
history

More Statistics

Revenue (TTM) (Mil) $64.02
EPS (TTM) $ -0.08
Beta0.33
Short Percentage of Float1.22%
52-Week Range $4.60 - 6.94
Shares Outstanding (Mil)56.91

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}